Teva seeks to launch generic Truvada, Gilead says

11/17/2008 | Reuters ·

Gilead Sciences said it was notified that Teva Pharmaceutical Industries filed for FDA approval to market a copy of Truvada, an HIV treatment combining Gilead's drugs Viread and Emtriva. Gilead, which has 45 days to file a patent-infringement suit against Teva, said 10 patents need to expire or be nullified before a generic version of Truvada can be launched.

View Full Article in:

Reuters ·

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX